Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.6 HKD | +2.84% | +15.56% | -15.27% |
04-30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
04-29 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.27% | 1.43B | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Presents Phase 1 Trial Data for Gastric/Gastroesophageal Cancer Drug